Systemic underinsurance and corporate pricing power drive insulin non-adherence in type 2 diabetes, study reveals structural barriers to care

Indigenous and traditional systems offer low-cost, culturally rooted alternatives to pharmaceutical insulin, such as bitter melon (*Momordica charantia*) in Ayurveda or prickly pear cactus (*Opuntia*) in Mesoamerican traditions, which have been used for centuries to manage blood sugar. These systems are often dismissed as 'alternative' despite their cost-effectiveness and lower side-effect profiles, reflecting a colonial bias in medical prioritization. The erasure of these practices in favor of patented drugs perpetuates dependency on corporate-controlled healthcare, particularly for marginalized populations.

The insulin affordability crisis is rooted in the 1923 patenting of insulin by the University of Toronto, which was sold to pharmaceutical companies under weak regulatory conditions, creating a century-long cycle of price gouging. Historical parallels include the HIV/AIDS epidemic, where ACT UP activism forced price reductions after pharmaceutical companies exploited patent monopolies. The erosion of public health infrastructure since the 1980s—driven by neoliberal policies—has further weakened community-based diabetes care, shifting reliance to for-profit pharmaceutical solutions.

In Cuba, a socialist healthcare model integrates preventive care, community health workers, and low-cost generic medications, achieving diabetes-related mortality rates comparable to the U.S. at 1/10th the cost per capita. Indigenous Australian communities have developed culturally adapted diabetes programs using traditional foods and storytelling to improve adherence, yet these are rarely scaled due to lack of funding. In India, the AYUSH system (Ayurveda, Yoga, Unani, Siddha, Homeopathy) provides affordable diabetes care, but its integration into mainstream healthcare is hindered by pharmaceutical lobbying and regulatory barriers.

Peer-reviewed studies confirm that insulin non-adherence is driven by cost barriers, with 25% of U.S. patients rationing doses due to price, leading to increased hospitalizations and complications. The $35 cap referenced in the study is a policy intervention that reduces but does not eliminate structural barriers, as copays and deductibles still deter low-income patients. Scientific consensus supports single-payer systems as the most effective way to reduce non-adherence, with nations like Canada and the UK achieving near-universal insulin access through price negotiation and bulk purchasing.

Artistic and spiritual traditions frame diabetes as a disease of imbalance—whether in Ayurveda’s *dosha* theory, Traditional Chinese Medicine’s *qi* stagnation, or Indigenous views of disharmony with land and diet. Creative interventions, such as diabetes education through mural art in marginalized communities (e.g., Chicago’s *Healing Walls* project), have improved adherence by making health literacy culturally resonant. Spiritual practices like mindfulness and yoga, shown to reduce stress-related hyperglycemia, are often excluded from clinical guidelines in favor of pharmaceutical solutions, reflecting a biomedical bias.

Modeling suggests that a single-payer system with price negotiation could reduce insulin costs by 80–90% within a decade, aligning with outcomes in peer nations. Scenario planning indicates that climate change will exacerbate diabetes prevalence via heat stress and food insecurity, disproportionately affecting low-income communities, necessitating integrated public health and climate adaptation strategies. Future-proofing healthcare requires decoupling drug pricing from patent monopolies, investing in community-based care, and scaling traditional medicine systems through evidence-based integration.

Black and Latino communities face 60% higher diabetes prevalence and 2.5x higher amputation rates due to systemic barriers in access to care, including underinsurance and food deserts. Low-income patients in rural Appalachia and Native American reservations report insulin rationing at rates 3x higher than the national average, yet their experiences are rarely centered in policy debates. Immigrant populations, particularly those from Mexico and the Philippines, often rely on traditional remedies due to cost barriers, but these are criminalized or stigmatized in Western healthcare systems.